Genprex

News

Genprex Receives U.S. FDA Fast Track Designation for Gene Therapy that Targets Lung Cancer

Genprex announced that the FDA has granted Fast Track Designation for Genprex’s Oncoprex™ immunogene therapy in combination with EGFR inhibitor osimertinib for the treatment of non-small cell lung cancer (NSCLC) patients with EFGR mutations that progressed after treatment with osimertinib alone.

Read More

Genprex to Present at Biotech Showcase™ 2020 in San Francisco

Genprex’s President and Chief Operating Officer, Julien Pham, MD, MPH, will lead the Company’s presentation and, along with Rodney Varner, the Company’s Chief Executive Officer, will be available for one-on-one investor meetings.

Read More

Genprex is Pioneering the Use of Non-Viral Vectors in Gene Therapy

Genprex is once again leading the way in gene therapy and raising the standard in cancer treatment based upon its unique, proprietary technology platform that includes its non-viral vector nanoparticle delivery system.

Read More

Genprex’s Non-Viral Delivery System Once Again Ahead of Recent Industry Research

Researchers at Johns Hopkins Medicine recently published a study in Science Advances that introduces a non-viral delivery system for gene editing. Genprex has already treated more than 50 patients in Phase I and II clinical trials using its proprietary non-viral delivery system.

Read More

In the money Nov. 25: $54M raised for drones, software, cancer-fighting drugs

Five companies in the past week reported more than $54 million in funding deals and securities offerings.

Read More

Genprex Announces $1.26 Million Registered Direct Offering

The company announced a registered direct offering of 3,167,986 shares of its common stock at a price to the public of $0.40 per share, for gross proceeds of approximately $1.26 million prior to deduction of commissions and offering expenses payable by Genprex.

Read More

Genprex Reports Positive Preclinical Data for the Treatment of Some of the Most Resistant Metastatic Lung Cancers

The company announced a registered direct offering of 3,167,986 shares of its common stock at a price to the public of $0.40 per share, for gross proceeds of approximately $1.26 million prior to deduction of commissions and offering expenses payable by Genprex.

Read More

Genprex Issues Lung Cancer Prevention Measures in Support of Lung Cancer Awareness Month

AUSTIN, Texas & CAMBRIDGE, Mass.— (November 4, 2019) — Genprex, Inc.(NASDAQ: GNPX), a clinical-stage gene therapy company, is publishing lung cancer prevention measures in an effort to educate the public, prevent new cases and raise awareness of lung cancer while supporting November’s Lung Cancer Awareness Month.

Each patient’s cancer is unique, but there are some preventive efforts that can be made to lower the risk of getting lung cancer….

Read More

Genprex to Present at the MicroCap Rodeo Investor Conference

AUSTIN, Texas & CAMBRIDGE, Mass.— (October 9, 2019) — Genprex, Inc.(NASDAQ: GNPX), a clinical-stage gene therapy company, today announced that it will be presenting at the inaugural MicroCap Rodeo Investor Conference in Austin, Texas on Tuesday, October 15 at 9:10 a.m. CDT.

Genprex’s Chairman and Chief Executive Officer, Rodney Varner, will lead the company’s presentation and will be available for one-on-one investor meetings….

Read More

Genprex’s Pioneering Use of Non-Viral Delivery for Gene Therapy is Gaining Industry Support

AUSTIN, Texas & CAMBRIDGE, Mass.— (October 7, 2019) — Genprex, Inc.(NASDAQ: GNPX), a clinical-stage company and leader in gene therapy using non-viral vector transfection delivery, wishes to draw attention to additional research in the field validating non-viral vector delivery as the next evolution in gene therapy.

A recently published paper by researchers in Australia, Spain and Austria supports the belief that non-viral delivery could be safer for patients than viral vectors and could speed up the production time while reducing the costs of production….

Read More